title: High prevalence of aspirin resistance in elderly patients with cardiovascular disease (CVD) and hyperhomocysteinaemia.
abstract: Although aspirin resistance is well reported in CVD, little is known about aspirin response in elderly patients with hyperhomocysteinaemia. The aim of the present study was to explore the prevalence of aspirin resistance in elderly patients with CVD and hyperhomocysteinaemia. A total of 370 elderly patients with CVD were recruited. The study included 216 patients with hyperhomocysteinaemia and 154 patients with normohomocysteinaemia receiving daily aspirin therapy (≥ 75 mg) over 1 month. The effect of aspirin was assessed using by light transmission aggregometry (LTA). Aspirin resistance was defined as ≥ 20% arachidonic acid induced aggregation according to LTA. Aspirin resistance was defined in 48 (13.0%) of 370 patients. The prevalence of aspirin resistance was higher in hyperhomocysteinaemic patients than normohomocysteinaemic patients (16.7% vs. 7.8%, odds ratio (OR)=2.367; 95% confidence interval (CI)=1.188-4.715, p=0.012). In the multivariate logistic regression analysis, hyperhomocysteinaemia (OR=2.406, 95% CI=1.201-4.820, p=0.013) was a significant risk factor for aspirin resistance. A significant number of CVD patients with hyperhomocysteinemia are resistant to aspirin therapy. Hyperhomocysteinemia is a significant risk factor for aspirin resistance in elderly patients with CVD.
authors.affiliation: Department of Clinical Laboratory of South Building, Chinese PLA General Hospital, Beijing, China.
authors.forename: Huaxin
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Pharmacy Department, Hospital of Chinese Peoples Armed Police Forces, Beijing 100039, PR China.
authors.forename: Xiuying
authors.initials: X
authors.lastname: Chen
authors.affiliation: Department of Respiratory Disease of South Building, Chinese PLA General Hospital, Beijing, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Liu
authors.affiliation: First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, China. Electronic address: calvin301@163.com.
authors.forename: Li
authors.initials: L
authors.lastname: Fan
authors.affiliation: First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, China. Electronic address: calvinisbest@hotmail.com.
authors.forename: Jian
authors.initials: J
authors.lastname: Cao
authors.affiliation: First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, China.
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Li
authors.affiliation: First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, China.
authors.forename: Guoliang
authors.initials: G
authors.lastname: Hu
authors.affiliation: First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, China.
authors.forename: Yixin
authors.initials: Y
authors.lastname: Hu
authors.affiliation: First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, China.
authors.forename: Bingpo
authors.initials: B
authors.lastname: Zhu
authors.affiliation: First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, China.
authors.forename: Xianfeng
authors.initials: X
authors.lastname: Liu
authors.affiliation: First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Gao
authors.affiliation: First Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, China.
authors.forename: Cong
authors.initials: C
authors.lastname: Ma
authors.affiliation: Second Geriatric Cardiology Division, Chinese PLA General Hospital, Beijing, China.
authors.forename: Wenxiu
authors.initials: W
authors.lastname: Leng
mesh_terms: D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002681:China; D004351:Drug Resistance; D005260:Female; D006801:Humans; D020138:Hyperhomocysteinemia / Q000188:drug therapy*; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D015995:Prevalence; D012307:Risk Factors
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin
keywords: Aspirin resistance; Cardiovascular disease; Hyperhomocysteinaemia